Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

56.50 +1.71 (+3.12%)

Streaming Delayed Price Updated: 3:31 PM EDT, Mar 31, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,676,901
Open	54.91
Bid (Size)	56.49 (100)
Ask (Size)	56.51 (100)
Prev. Close	54.79
Today's Range	54.91 - 56.58
52wk Range	50.76 - 71.28
Shares Outstanding	183,352,255
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky

March 26, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Performance

YTD	-5.0%	-5.0%
1 Month	-5.4%	-5.4%
3 Month	-5.9%	-5.9%
6 Month	+4.6%	+4.6%
1 Year	-20.1%	-20.1%

More News

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

Via The Motley Fool

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

March 16, 2026

Via Chartmill

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss ↗

February 23, 2026

Via Chartmill

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

January 24, 2026

Via Chartmill

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate ↗

January 02, 2026

Via Chartmill

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

March 19, 2026

Via StockStory

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

Via The Motley Fool

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

Via The Motley Fool

2 Mid-Cap Stocks with Exciting Potential and 1 We Question

March 12, 2026

Via StockStory

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

Via The Motley Fool

2 Reasons to Like BMRN (and 1 Not So Much)

March 02, 2026

Via StockStory

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Via The Motley Fool

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

February 23, 2026

Via StockStory

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

February 21, 2026

Via StockStory

Should You Buy BioMarin Pharmaceutical Before Feb. 18? ↗

January 31, 2026

Via The Motley Fool

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

January 08, 2026

Via StockStory

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

Via MarketMinute

10 Magnificent Stocks That Can Make You Richer in 2026 ↗

January 05, 2026

Via The Motley Fool

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Via MarketMinute

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq

December 23, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?

Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?

BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?

The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market

What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?

The current price of BioMarin Pharmaceutical Inc. - Common Stock is 56.50

When was BioMarin Pharmaceutical Inc. - Common Stock last traded?

The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 03/31/26 03:31 PM ET

What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?

The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 10.36B

How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?

BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.